小分子靶向治疗联合肝动脉栓塞化疗术治疗对晚期肝癌患者临床疗效及生存时间的影响

Effect of small-molecule targeted therapy combined with hepatic artery embolization chemotherapy on clinical efficacy and survival time of patients with advanced liver cancer

目的探析晚期肝癌患者应用小分子靶向治疗联合肝动脉栓塞化疗术治疗的临床疗效以及对患者生存时间的影响。方法90例晚期肝癌患者,通过随机数字表法分为对照组及观察组,每组45例。对照组行单纯肝动脉栓塞化疗术治疗,观察组应用小分子靶向治疗联合肝动脉栓塞化疗术治疗。比较两组临床疗效、生存情况(无进展生存期、生存时间)及不良反应发生情况。结果观察组患者显效率46.67%、总有效率95.56%均高于对照组的24.44%、80.00%,差异有统计学意义(P<0.05)。观察组患者的无进展生存期(6.68±0.75)个月、生存时间(12.65±0.74)个月均长于对照组的(3.52±1.05)、(8.95±1.52)个月,差异有统计学意义(P<0.05)。两组不良反应发生率对比差异无统计学意义(P>0.05)。结论晚期肝癌患者接受小分子靶向治疗联合肝动脉栓塞化疗术治疗,治疗效果相比于单一肝动脉栓塞化疗术更高,可有效延长患者的生存期,此种联合治疗方式更值得临床推广普及。

Objective To discuss the effect of small-molecule targeted therapy combined with hepatic artery embolization chemotherapy on clinical efficacy and survival time of patients with advanced liver cancer.Methods A total of 90 patients with advanced liver cancer were divided into control group and observation group by random numerical table,with 45 cases in each group.The control group was treated with simple hepatic artery embolization chemotherapy,and the observation group was treated with small-molecule targeted therapy and hepatic artery embolization chemotherapy.The clinical efficacy,survival status(progression-free survival,survival time)and occurrence of adverse reactions were compared between the two groups.Results The significant rate 46.67%and total effective rate 95.56%in the observation group were higher than 24.44%and 80.00%in the control group,and the difference was statistically significant(P<0.05).The progression-free survival(6.68±0.75)months and survival time(12.65±0.74)months of the observation group were longer than(3.52±1.05)and(8.95±1.52)months of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Small-molecule targeted therapy in combination with hepatic artery embolization chemotherapy has better therapeutic effect on patients with advanced liver cancer than that of single hepatic artery embolization chemotherapy,and it can effectively prolong the survival of patients,this combination therapy is more worthy of clinical promotion and popularization.